Advertisement

Picture EBD Group Asia Bio Partnering Forum 2024 Singapore 650x100px
Collaboration › Details

Remix Therapeutics–JPMorgan Chase: investor conference, 202401 supply service Remix presents at JP Morgan Healthcare Conference 2024

 

Period Period 2024-01-10
Region Region San Francisco, CA
  Country United States (USA)
Organisations Partner, 1st Remix Therapeutics Inc.
  Partner, 2nd J.P. Morgan Securities LLC
  Group JPMorgan Chase (Group)
Products Product J.P. Morgan 42nd Annual Healthcare Conference 2024 San Francisco
  Product 2 REMaster™ technology platform
Persons Person Smith, Peter (Pete) (Remix Therapeutics 202012 CSO + Co-Founder)
  Person 2 O’Connor, Will (Precision Medicine Group 202004 at Stern IR)
     

Remix Therapeutics, Inc.. (12/21/23). "Press Release: Remix Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference". Watertown, MA.

Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced that Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix, will present a corporate overview at the 42nd Annual J.P. Morgan Healthcare Conference in San Fransisco on Wednesday, January 10, 2024, at 10:30 a.m. PT at The Westin St. Francis in the Mission Bay room.


About Remix Therapeutics

Remix Therapeutics is a biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and treat disease. The REMaster™ technology platform facilitates RNA processing pattern identification, leveraging these learnings to modulate gene expression. Remix’s innovative therapeutic approach has the ability to alter the way genes are read from the genome, to correct, enhance, or eliminate the gene message, thereby addressing disease drivers at their origin. For more information visit www.remixtx.com.


Media Contact
LISETTE STEELE
Verge Scientific Communications
202.930.4762
lsteele@vergescientific.com

Investor Contact
WILL O’CONNOR
Stern Investor Relations
212.326.1200
will.oconnor@sternir.com

   
Record changed: 2024-01-03

Advertisement

Picture [iito] [LSE] Life-Sciences-Europe.com Business Portal 650x200px

More documents for Remix Therapeutics Inc.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group Bio-Europe Spring 2024 Barcelona 650x300px




» top